Position in CELC
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$31,789,833
+$4,219,431 QoQ
Shares Held
303,860
+25.8% QoQ
Ownership
0.621%
of shares outstanding
% of Portfolio
0.18%
of 13F equity value
Holder Rank
#40
of 274 holders
Holding Since
Mar 2024
6 quarters on record
Voting authority
Sole 78%
Shared 0%
None 22%
Common Shares in CELC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Driehaus Capital Management LLC holds $3,707,249,767 across 60 Biotechnology names. CELC ranks #25 (0.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | DFTX |
Definium Therapeutics, Inc.
|
6,845,276 | $322,001,783 | |
| 2 | PRAX |
Praxis Precision Medicines, Inc.
|
959,048 | $321,079,679 | |
| 3 | XENE |
Xenon Pharmaceuticals Inc.
|
4,418,557 | $266,704,100 | |
| 4 | SYRE |
Spyre Therapeutics, Inc.
|
2,799,166 | $248,509,957 | |
| 5 | CRNX |
Crinetics Pharmaceuticals, Inc.
|
6,463,551 | $241,866,078 | |
| 6 | APGE |
Apogee Therapeutics, Inc.
|
1,740,101 | $230,963,605 | |
| 7 | EWTX |
Edgewise Therapeutics, Inc.
|
4,728,623 | $192,123,952 | |
| 8 | SEPN |
Septerna, Inc.
|
4,433,058 | $148,463,112 |
All Filings in CELC
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $31,789,833 | 303,860 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $27,570,402 | 241,549 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $24,940,485 | 250,055 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $8,015,446 | 162,256 | Shares | Sole | 2025-11-14 | |
| 2024-06-30 | $3,351,216 | 204,592 | Shares | Sole | 2024-08-15 | |
| 2024-03-31 | $2,723,047 | 126,067 | Shares | Sole | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||